{
    "Trade/Device Name(s)": [
        "Healgen Multi-Drug Urine Test Cup",
        "Healgen Multi-Drug Urine Test Dip Card"
    ],
    "Submitter Information": "HEALGEN SCIENTIFIC LLC",
    "510(k) Number": "K150356",
    "Predicate Device Reference 510(k) Number(s)": [
        "K142280",
        "K143187",
        "K141647",
        "K140546"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JXM",
        "DJG",
        "DIO",
        "LDJ",
        "LAF",
        "DKZ"
    ],
    "Summary Letter Date": "April 14, 2015",
    "Summary Letter Received Date": "April 17, 2015",
    "Submission Date": "May 8, 2015",
    "Regulation Number(s)": [
        "21 CFR 862.3100",
        "21 CFR 862.3170",
        "21 CFR 862.3250",
        "21 CFR 862.3610",
        "21 CFR 862.3650",
        "21 CFR 862.3870"
    ],
    "Regulation Name(s)": [
        "Amphetamine Test System",
        "Benzodiazepine Test System",
        "Cocaine and Cocaine Metabolites Test System",
        "Methamphetamine Test System",
        "Opiate Test System",
        "Cannabinoids Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Amphetamine",
        "Oxazepam",
        "Cocaine",
        "Cannabinoids",
        "Methamphetamine",
        "Morphine",
        "Oxycodone"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow assay",
        "Competitive binding"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Cup",
        "Dip Card"
    ],
    "Document Summary": "FDA 510(k) summary for Healgen Multi-Drug Urine Test Cup and Dip Card for qualitative multi-analyte drug detection in urine using competitive immunochromatographic lateral flow assay.",
    "Indications for Use Summary": "Qualitative and simultaneous detection of amphetamine, oxazepam, cocaine, cannabinoids, methamphetamine, morphine, and oxycodone in human urine at defined cutoff concentrations; provides preliminary results, confirmatory testing by GC/MS or LC/MS recommended.",
    "fda_folder": "Toxicology"
}